Phreesia, Inc. (NYSE:PHR – Get Free Report) COO Evan Roberts sold 3,148 shares of Phreesia stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total transaction of $73,191.00. Following the transaction, the chief operating officer now directly owns 755,719 shares in the company, valued at approximately $17,570,466.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Evan Roberts also recently made the following trade(s):
- On Tuesday, July 16th, Evan Roberts sold 1,669 shares of Phreesia stock. The shares were sold at an average price of $23.74, for a total transaction of $39,622.06.
Phreesia Trading Up 3.9 %
Shares of NYSE PHR opened at $24.68 on Friday. Phreesia, Inc. has a 1-year low of $12.05 and a 1-year high of $29.16. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.77 and a quick ratio of 1.77. The business’s 50 day moving average is $23.72 and its two-hundred day moving average is $22.75. The stock has a market capitalization of $1.42 billion, a P/E ratio of -11.37 and a beta of 0.93.
Hedge Funds Weigh In On Phreesia
Wall Street Analysts Forecast Growth
PHR has been the topic of a number of recent analyst reports. Royal Bank of Canada reissued a “sector perform” rating and set a $23.00 price target on shares of Phreesia in a report on Thursday, September 5th. KeyCorp dropped their price target on Phreesia from $27.00 to $25.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Needham & Company LLC reiterated a “buy” rating and set a $29.00 price objective on shares of Phreesia in a research report on Thursday, September 5th. Stephens reissued an “overweight” rating and issued a $28.00 target price on shares of Phreesia in a report on Friday, May 31st. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $34.00 target price on shares of Phreesia in a research note on Thursday, September 5th. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $29.42.
View Our Latest Analysis on Phreesia
About Phreesia
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
See Also
- Five stocks we like better than Phreesia
- What Are Dividend Champions? How to Invest in the Champions
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- How to Plot Fibonacci Price Inflection Levels
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- High Flyers: 3 Natural Gas Stocks for March 2022
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.